The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Regulatory News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Diurnal Group plc

28 Oct 2022 13:26

RNS Number : 5291E
Barclays PLC
28 October 2022
 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR

MORE

Rule 8.3 of the Takeover Code (the "Code")

1.

KEY INFORMATION

(a)

Full name of discloser:

 

Barclays PLC.

(b)

Owner or controller of interest and short

 

 

positions disclosed, if different from 1(a):

(c)

Name of offeror/offeree in relation to whose

DIURNAL GROUP PLC

 

relevant securities this form relates:

(d)

If an exempt fund manager connected with an

 

 

offeror/offeree, state this and specify identity of

 

offeror/offeree:

(e)

Date position held/dealing undertaken:

27 Oct 2022

(f)

In addition to the company in 1(c) above, is the discloser making

NO

 

 

 

disclosures in respect of any other party to the offer?

 

 

2.

POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a)

Interests and short positions in the relevant securities of the offeror or offeree

 

 

to which the disclosure relates following the dealing(if any)

 

Class of relevant security:

5p ordinary

 

Interests

Short Positions

 

Number

(%)

Number

(%)

(1)

Relevant securities owned

 

 

 

 

 

and/or controlled:

 

 

2,315,595

1.36%

0

0.00%

(2)

Cash-settled derivatives:

 

 

 

 

 

and/or controlled:

 

 

0

0.00%

2,315,595

1.36%

(3)

Stock-settled derivatives (including options)

 

 

 

 

 

and agreements to purchase/sell:

 

 

0

0.00%

0

0.00%

 

 

 

 

 

 

 

 

 

TOTAL:

 

 

2,315,595

1.36%

2,315,595

1.36%

(b)

Rights to subscribe for new securities (including directors and other executive

 

 

options)

 

 

 

 

 

 

Class of relevant security in relation to

 

 

 

 

which subscription right exists

 

 

 

 

Details, including nature of the rights

 

 

 

 

concerned and relevant percentages:

 

 

 

 

3.

DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

(a)

Purchases and sales

 

 

 

 

 

Class of relevant

Purchase/sale

Number of

Price per unit

security

 

securities

 

5p ordinary

Purchase

2,315,595

0.2747 GBP

 

 

 

 

 

 

 

 

(b)

Cash-settled derivative transactions

 

Class of

Product

Nature of dealing

Number of

Price per

relevant

description

 

reference

unit

security

 

 

securities

 

5p ordinary

SWAP

Short

2,315,595

0.2747 GBP

 

 

 

 

 

 

 

 

(c)

Stock-settled derivative transactions (including options)

 

(i)

Writing, selling, purchasing or varying

 

Class

Product

Writing,

Number

Exercise

Type

Expiry

Option

of

description

purchasing,

of

price

 

date

money

relevant

 

selling,

securities

per unit

 

 

paid/

security

 

varying etc

to which

 

 

 

received

 

 

 

option

 

 

 

per unit

 

 

 

relates

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(ii)

Exercising

 

 

 

 

 

 

Class of relevant

Product description

Exercising/ exercised against

Number of

Exercise price per

security

 

 

securities

unit

 

 

 

 

 

 

 

 

 

 

 

 

 

(d)

Other dealings (including subscribing for new securities)

 

Class of relevant

Nature of Dealings

Details

Price per unit (if

security

 

 

applicable)

 

 

 

 

4.

OTHER INFORMATION

(a)

Indemnity and other dealings arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding,

 

 

formal or informal, relating to relevant securities which may be an inducement to deal

 

 

or refrain from dealing entered into by the exempt principal trader making the disclosure and any party

 

to the offer or any person acting in concert with a party to the offer:

 

 

 

NONE

(b)

Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between

 

 

the person making the disclosure and any other person relating to:

 

 

(i) the voting rights of any relevant securities under any option; or

 

 

 

(ii) the voting rights of future acquisition or disposal of any relevant securities to which

 

 

any derivative is referenced:

 

 

 

 

 

 

NONE

(c)

Attachments

 

 

 

 

 

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:

28 Oct 2022

Contact name:

Large Holdings Regulatory Operations

Telephone number:

020 3134 7213

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RETMPBTTMTTTBAT
Date   Source Headline
6th Mar 202011:22 amRNSProposed Placing
5th Mar 20204:41 pmRNSDirectorate Change
28th Feb 20207:30 amEQSHardman & Co Research: Diurnal (DNL): . and more to come (news flow)
25th Feb 20203:06 pmRNSHolding(s) in Company
20th Feb 20204:41 pmRNSSecond Price Monitoring Extn
20th Feb 20204:36 pmRNSPrice Monitoring Extension
20th Feb 202011:00 amRNSPrice Monitoring Extension
17th Feb 20201:46 pmRNSHolding(s) in Company
13th Feb 20207:00 amRNSUS FDA Accepts NDA Application for Alkindi
11th Feb 20207:00 amRNSInterim Results
20th Jan 20207:00 amRNSBusiness and trading update
13th Jan 20207:00 amRNSNotice of Interim Results
13th Jan 20207:00 amRNSHolding(s) in Company
10th Jan 20203:45 pmRNSDirector Dealings and Issue of Equity
10th Jan 20203:44 pmRNSIssue of Long-Term Incentive Plan awards
16th Dec 201911:46 amRNSDirector Dealings
16th Dec 20197:00 amRNSChronocort MAA Submitted in Europe
2nd Dec 20192:28 pmRNSShare Option Exercise and Issue of Equity
2nd Dec 20197:01 amRNSHolding(s) in Company
2nd Dec 20197:00 amRNSAlkindi New Drug Application Submitted to US FDA
26th Nov 201910:42 amRNSDirector Dealings and Issue of Equity
26th Nov 20197:15 amEQSHardman & Co Research: Diurnal (DNL): Successful DITEST Phase I trial outcome
21st Nov 20191:08 pmRNSResults of Annual General Meeting
21st Nov 20197:00 amRNSAGM Statement
20th Nov 20197:00 amRNSSuccessful outcome of testosterone clinical study
8th Nov 20197:00 amRNSVesting of LTIP awards
5th Nov 20197:30 amEQSHardman & Co Research: Diurnal (DNL): Approaching a number of near-term milestones
21st Oct 20196:23 pmRNSIssue of Equity
21st Oct 20191:09 pmRNSDirector Dealings
8th Oct 201911:26 amRNSPosting of Annual Report and AGM Notice
24th Sep 20197:00 amRNSResults for the year ended 30 June 2019
7th Aug 201911:04 amRNSDirector Dealings
5th Aug 201912:27 pmRNSDirector/PDMR Shareholding
26th Jul 20194:32 pmRNSHolding(s) in Company
8th Jul 20192:07 pmRNSDirector Dealings and Issue of Equity
3rd Jul 20197:00 amRNSMarket Authorisation Application in Australia
26th Jun 20193:57 pmRNSHolding(s) in Company
24th Jun 20199:39 amRNSDirector Dealings
21st Jun 20193:40 pmRNSHolding(s) in Company
21st Jun 20193:35 pmRNSHolding(s) in Company - Replacement
21st Jun 201910:18 amRNSChange of Auditor
19th Jun 20194:08 pmRNSHolding(s) in Company
18th Jun 20195:30 pmRNSHolding(s) in Company
18th Jun 20192:03 pmRNSDirector Dealings
17th Jun 201912:05 pmRNSDirector Dealings
14th Jun 201912:39 pmRNSResult of General Meeting and Issue of Equity
14th Jun 20197:00 amRNSResult of Open Offer
28th May 20197:00 amRNSPlacing, Open Offer and Notice of General Meeting
9th May 20197:00 amRNSIntent to Submit for MAA tendered to the EMA
2nd May 20193:29 pmRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.